Henlius announced that their multicenter phase III study met its primary end point of best overall response rate at week 24.
HER2-Positive Breast Cancer
Oncotype DX® Breast Recurrence Scores from the National Cancer Database indicated that a lower threshold is needed for male patients with early stage ER-positive breast cancer to predict mortality.
PRS-343, a HER2/4-1BB targeting bispecific construct, is well-tolerated and demonstrated anti-tumor activity in heavily pre-treated patient population across multiple tumor types.
Treatment with trastuzumab emtansine demonstrated similar overall survival across 3 treatment arms of patients with HER2‐positive metastatic breast cancer.
MCLA-128 showed radiological and clinical responses in patients with certain types of cancer who harbored neuregulin 1 gene fusions.
Tucatinib showed improvements in survival in patients with HER2-positive breast cancer.
Two trials and 3000 patients with HER2-positive breast cancer were analyzed for recurrence risk 5 to 10 years after diagnosis.
Several clinicopathologic features of HER2-positive breast cancer patients were found to be associated with response to neoadjuvant therapy in a new study.
The trial examined HER2-positive breast cancer in patients with tumors smaller than 1cm; it is one of only a few to assess treatments in tumors this small.
A new study found a low rate of cancer recurrence at the nipple-areola complex (NAC) in patients with breast cancer who underwent nipple-sparing mastectomy (NSM).